Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Immunotherapies (ITs) significantly improved patient survival in France. This study found ITs prevented deaths and gained life-years and quality-adjusted life years compared to standard care.
Area Of Science
- Oncology
- Immunotherapy
- Health Economics
Background
- Limited long-term data on immunotherapy (IT) benefits at a population level in France.
- Haute Autorité de Santé (HAS) primarily evaluates new treatments for reimbursement, not post-market long-term impact.
- Retrospective study to assess clinical benefit of ITs versus standard of care (SoC) from 2014-2021.
Purpose Of The Study
- To evaluate the real-world clinical benefit of immunotherapies (ITs) in France.
- Compare ITs (anti-PD-(L)1) against previous standards of care (SoCs).
- Quantify gains in deaths prevented (DP), life-years (LYs), and quality-adjusted life years (QALYs).
Main Methods
- Analysis of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-(L)1) ITs used in monotherapy or combination.
- Inclusion of treatments available via early access or reimbursement in France (2014-2021).
- Extrapolation of Kaplan-Meier curves, utility scores, and population data to estimate DP, LYs, and QALYs gained.
Main Results
- 132,924 patients initiated ITs between 2014-2021 across 21 indications.
- 16,173 deaths were delayed by December 2021 compared to SoC.
- ITs yielded 37,316 additional LYs and 27,709 additional QALYs, primarily driven by lung cancer and melanoma.
Conclusions
- Introduction of ITs in France has led to substantial clinical benefits.
- Significant gains observed in deaths prevented, life-years, and quality-adjusted life years.
- ITs represent a major advancement in cancer treatment outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...